Inovio Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Inovio Pharmaceuticals (INO) shares fell 2.48% to $1.18 on Friday, underperforming the broader market and key competitors like Johnson & Johnson and Pfizer during a positive trading session. This marks the stock's second consecutive day of losses, with prices currently 60.39% below its 52-week high of $2.98. Trading volume reached 5.0 million, exceeding the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Inovio Pharmaceuticals Inc. (INO) slipped 2.48% to $1.18 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 0.43% to 26,180.45 and the Dow Jones Industrial Average rising 0.98% to 53,277.01.
This was the stock's second consecutive day of losses.
Inovio Pharmaceuticals Inc. closed 60.39% short of its 52-week high of $2.98, which the company achieved on September 9th.
The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) rose 1.07% to $270.24, Statera Biopharma Inc. (STAB) remained unchanged, and Pfizer Inc. (PFE) rose 1.01% to $28.07.
Trading volume (5.0 M) eclipsed its 50-day average volume of 3.5 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 21, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-21-26 1724ET